0000000000610223

AUTHOR

Jan Gerstoft

showing 3 related works from this author

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

2018

PubMed: 29599078

0301 basic medicineBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences.HBsAgPediatricsDelphi TechniqueInfectious Disease TransmissionCHRONIC HBV INFECTION ; NATURAL-HISTORY ; FOLLOW-UP ; HBSAG ; CARRIERS ; AGE ; COUNTRIES ; DISEASE ; ANTIGEN ; COHORTddc:616.07Global Healthmedicine.disease_causeDISEASE0302 clinical medicinePrevalenceHBVChildddc:616Antiviral Agents/therapeutic useeducation.field_of_studyBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti.Chronic/drug therapy/epidemiology/prevention & control/transmissionGastroenterologyHepatitis B Surface Antigens/bloodHepatitis BCARRIERSHepatitis B10219 Clinic for Gastroenterology and HepatologyChild Preschool030211 gastroenterology & hepatologyViral hepatitisViral loadCOUNTRIESAdultmedicine.medical_specialtyHepatitis B vaccineANTIGENPopulation610 Medicine & healthAntiviral AgentsMass VaccinationHepatology; Gastroenterology03 medical and health sciencesHepatitis B ChronicHBSAGAGESDG 3 - Good Health and Well-beingmedicineHumansCOHORT2715 GastroenterologyPreschooleducationDisease burdenHepatitis B virusHepatitis B Surface AntigensHepatologybusiness.industryViral VaccinesNATURAL-HISTORYmedicine.diseaseInfectious Disease Transmission VerticalCHRONIC HBV INFECTIONVertical/prevention & control030104 developmental biology2721 HepatologyHuman medicineFOLLOW-UPbusiness
researchProduct

Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance

2016

Udgivelsesdato: 2009-May-03 Although cytotoxic T lymphocytes (CTLs) in people infected with human immunodeficiency virus type 1 can potentially target multiple virus epitopes, the same few are recognized repeatedly. We show here that CTL immunodominance in regions of the human immunodeficiency virus type 1 group-associated antigen proteins p17 and p24 correlated with epitope abundance, which was strongly influenced by proteasomal digestion profiles, affinity for the transporter protein TAP, and trimming mediated by the endoplasmatic reticulum aminopeptidase ERAAP, and was moderately influenced by HLA affinity. Structural and functional analyses demonstrated that proteasomal cleavage 'prefer…

Models MolecularProteasome Endopeptidase ComplexHIV AntigensMolecular Sequence DataImmunologyAntigen presentationHIV Core Protein p24HIV InfectionsImmunodominanceMajor histocompatibility complexgag Gene Products Human Immunodeficiency VirusEpitopeEvolution MolecularMajor Histocompatibility ComplexLeucyl Aminopeptidase03 medical and health sciences0302 clinical medicineAntigenHumansImmunology and AllergyCytotoxic T cellAmino Acid Sequence030304 developmental biologyAntigen Presentation0303 health sciencesHLA-A AntigensbiologyImmunodominant EpitopesAntigen processingVirology3. Good healthCTL*MutationHIV-1biology.proteinATP-Binding Cassette TransportersProtein BindingT-Lymphocytes Cytotoxic030215 immunologyRETROVIROLOGY
researchProduct

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling…

2017

Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting antiviral therapies began in 2014. WHO targets are to achieve a 65% reduction in liver-related deaths, a 90% reduction of new viral hepatitis infections, and 90% of patients with viral hepatitis infections being diagnosed by 2030. This study assessed the prevalence of HCV in the EU and the level of intervention required to achieve WHO targets for HCV elimination. Methods We populated country Markov models for the 28 EU countries through a literature search of PubMed and Embase between Jan 1, 2000, and March 31, 201…

Pediatricsddc:616.07medicine.disease_cause0302 clinical medicineCost of IllnessEpidemiologyPrevalenceEPIDEMIOLOGY030212 general & internal medicineSettore SECS-P/01 - Economia PoliticaCIRRHOSISmedia_commonddc:616Antiviral Agents/therapeutic useeducation.field_of_studyINJECT DRUGSGastroenterologyHCV INFECTIONvirus diseasesHepatitis CEmigration and ImmigrationDISEASE BURDENHepatitis CMarkov ChainsEmigration and Immigration/statistics & numerical data030211 gastroenterology & hepatologyViral hepatitisModelling ; Eradication ; European Union ; Hepatitis C ; prevalenceCOUNTRIESmedicine.medical_specialtyHepatitis C virusPopulationUNITED-STATESWorld Health OrganizationAntiviral Agents03 medical and health sciencesSDG 3 - Good Health and Well-beingPEOPLEInternal medicineIntervention (counseling)medicineJournal Articlemedia_common.cataloged_instanceHumansEuropean UnionViremiaEuropean unionDisease EradicationeducationHepatitis C/diagnosis/drug therapy/epidemiology/prevention & controlHepatologybusiness.industryViremia/diagnosis/drug therapy/epidemiology/prevention & controlHepatologymedicine.diseaseVirologyPREVENTIONdigestive system diseasesHuman medicineVIRAL-HEPATITISbusinessLancet Gastroenterology & Hepatology
researchProduct